SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Stock
Equities
002864
CNE1000032C9
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.77 CNY | -0.15% |
|
-4.77% | -30.45% |
| Sales 2023 * | 1.15B 159M | Sales 2024 * | 1.47B 202M | Capitalization | 2.81B 389M |
|---|---|---|---|---|---|
| Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 * | 2.44 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 1.92 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 935 |
| Yield 2023 * |
0.75% | Yield 2024 * |
0.75% | Free-Float | 58.59% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.15% | ||
| 1 week | -4.77% | ||
| Current month | -7.85% | ||
| 1 month | -18.61% | ||
| 3 months | -24.19% | ||
| 6 months | -28.77% | ||
| Current year | -30.45% |
1 week
25.50
27.82
1 month
25.5032.46
Current year
22.0040.50
1 year
22.0051.57
3 years
21.4376.66
5 years
21.0076.66
10 years
12.0481.36
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Lin Xie
CEO | Chief Executive Officer | 56 | 13-06-15 |
Feng Ming Zhu
DFI | Director of Finance/CFO | 53 | 13-06-15 |
Jie Wu
BRD | Director/Board Member | 54 | 13-06-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhi Hong Zhang
BRD | Director/Board Member | 60 | 13-06-15 |
Jie Wu
BRD | Director/Board Member | 54 | 13-06-15 |
Xiao Lin Xie
CEO | Chief Executive Officer | 56 | 13-06-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 26.77 | -0.15% | 1 578 504 |
| 24-04-18 | 26.81 | -0.11% | 2,189,700 |
| 24-04-17 | 26.84 | +5.25% | 2,803,337 |
| 24-04-16 | 25.5 | -5.49% | 3,324,943 |
| 24-04-15 | 26.98 | -2.81% | 3,067,000 |
End-of-day quote Shenzhen S.E., April 18, 2024
More quotes
SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD is a China-based company principally engaged in the research, development, manufacture and sales of Chinese patent drugs. The Company's main product is Panlong Qipian, which is for the treatment of orthopedic rheumatism diseases. The Company also provides other Chinese patent drugs for the treatment of hepatobiliary, cardiovascular and cerebrovascular, gynecological and anti-tumor diseases. The Company is also involved in the production and sales of Chinese herbal pieces, as well as the medical commercial distribution business. The Company distributes its products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
26.77
CNY
Average target price
41.72
CNY
Spread / Average Target
+55.85%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.45% | 389M | |
| +24.50% | 672B | |
| +24.08% | 550B | |
| -5.82% | 351B | |
| +15.45% | 317B | |
| +7.21% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.83% | 144B | |
| -6.62% | 141B |
- Stock Market
- Equities
- 002864 Stock
